A recent study shows DNA sequencing brings greater precision to childhood cancer. Using genomic technology to analyze both tumor and blood samples from a large number of children who’d been newly diagnosed with cancer, an National Institutes of Health-funded research team uncovered genetic clues with...
On the 23rd of March NCCN convened a working group to consider TP53 mutation carriage and develop consistent advice on how this should be managed in the New Zealand child cancer population. Current working group members include: Kim Gamet, Genetic Health Service NZ – Northern Hub ...
NCCN has recently completed the development of an online tool to support the Shared Care Agreements process. The tool will facilitate communications both within Shared Care Centres and between Shared Care and Specialist Centres and create an evolving working record of service delivery arrangements.NCCN will...
NCCN recently hosted a symposium on targeted therapy in paediatric oncology, featuring guest speaker Dr Katie Janeaway from Harvard Medical School and Boston Children’s Hospital, moderator Professor Geoff McCowage from Sydney Children’s Hospital Network at Westmead and local presenter Dr Andrew Wood, Paediatric Oncologist at...
Dr Scott Macfarlane (National Clinical Leader; Child Cancer) was awarded an Honorary Lifetime Membership by the Child Cancer Foundation. Presented by the Governor General, Lt Gen Rt Hon Sir Jerry Mateparae, at Government House in Auckland. This rare honour (only 20 memberships awarded) recognises Scott’s...